Bevacizumab联合吉西他滨对荷肝癌裸鼠移植瘤生长的抑制作用  

Bevacizumab Combined with Gemcitabine Inhibit the Growth of Hepatocellular Carcinoma Tumor Xenografts in Nude Mice

作　　者：万骋[1] 崔斐[2] 张苗[1] 罗荣城[2] 

机构地区：[1]南京大学医学院附属鼓楼医院肾内科,江苏南京210008 [2]南方医科大学南方医院肿瘤中心,广东广州510515

出　　处：《现代生物医学进展》2012年第10期1865-1867,共3页Progress in Modern Biomedicine

摘　　要：目的:探讨抗血管生成药物Bevacizumab联合吉西他滨对人肝癌裸鼠皮下移植瘤生长的抑制作用。方法:构建人肝癌细胞HepG2裸鼠皮下移植瘤模型,随机分为空白对照组、Bevacizumab组、吉西他滨组和联合用药组。观察用药前后肿瘤体积,绘制肿瘤生长曲线;应用免疫组化检测肿瘤微血管密度(MVD);Western Blot检测Bcl-2蛋白的表达。结果:Bevacizumab和吉西他滨单药均能抑制肿瘤生长,两药联合疗效明显增强(P=0.000)。与对照组和吉西他滨组相比,Bevacizumab组和联合用药组能明显抑制肿瘤血管生成,MVD值均明显降低,以联合用药组最为明显(P均0.000)。Bevacizumab和吉西他滨单药均能下调Bcl-2的表达,两药联合下调作用明显增强。结论:Bevacizumab联合吉西他滨能增强对人肝癌裸鼠移植瘤的生长及微血管生成的抑制作用,其机制可能与调控Bcl-2的表达有关。Objective： To investigate inhibitory effect of Bevacizumab combined with gemcitabine against HepG2 hepatocellul ar carcinoma（HCC） tumor xenografts.Methods： Established HepG2 HCC xenograft models.Mice were divided into four groups： untreated control group,Bevacizumab treated group,gemcitabine treated group and combination treatment group.Tumor volumes were recorded and microvessel density（MVD） was examined by immunohistochemistry.The expression of Bcl-2 was evaluated by western blot.Results： Bevacizumab and gemcitabine alone inhibits the growth of HepG2 HCC tumor xenografts.The efficacy of combination was significantly better than Bevacizumab or gemcitabine administered alone（P =0.000）.The immunohistochemistry results showed that the MVD were reduced in Bevacizumab group,especially in combination groups（P=0.000）.In addition,Bevacizumab and gemcitabine alone reduced Bcl-2 expression in tumor tissues,especially in combination groups.Conclusion： Bevacizumab combined with gemcitabine can greatly inhibit the growth and angiogenesis of tumor in HCC xenograftmodels via an inhibition of Bcl-2 expression possibly.

关 键 词：肝细胞癌 BEVACIZUMAB 吉西他滨 微血管密度 BCL-2 

分 类 号：Q95-33[生物学—动物学] R357[医药卫生—基础医学]